MedX Health Corp. Announces Non-Brokered Private Placement

    0
    257
    Reading Time: 3 minutes

    MISSISSAUGA, Ontario–(BUSINESS WIRE)–MedX Health Corp.:

    NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO
    U.S. NEWSWIRE SERVICES

    MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX)
    is pleased to announce that it has obtained Conditional Approval from
    the TSX Venture Exchange for a non-brokered Private Placement to
    accredited investors of up to 15,625,000 units at $0.16 per unit
    (“Unit”), to raise up to $2,500.000. Each Unit will be comprised of One
    (1) fully paid common share and One (1) Share Purchase Warrant,
    exercisable to purchase One (1) further Common Share at the price of
    $0.25, exercisable for a period of two years from the date of issue.
    Closing of the Placement, which will take place in tranches, will be
    subject to receipt of subscriptions and a number of other conditions,
    including without limitation the receipt of all relevant regulatory and
    Stock Exchange approvals or acceptances. Qualified Agents may receive
    commissions in respect of subscriptions introduced by them by way of
    cash equal to 6% of funds so introduced, and issuance of agent’s
    warrants (“Agent’s Warrant(s)”) equal in number to 6% of the number of
    units so subscribed for. Each Agent’s Warrant, which is
    non-transferable, will be exercisable to acquire one Unit at $0.16 per
    Unit, at any time during the period of two years following the Closing.
    The first Closing of this private placement has taken place on April 26,
    2019, to raise $282,600 by issuance of 1,766,250 Units. In connection
    with the first Closing, a cash commission of $12,960 was paid and 79,350
    Agent’s Warrants were issued.

    Following this Closing, MedX has 139,782,651 common shares issued and
    outstanding.

    About MedX

    MedX, headquartered in Mississauga, Ontario, is a leading medical device
    and software company focused on skin cancer with its DermSecure™
    telemedicine platform, utilizing its SIAscopy technology. SIAscopy is
    also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which
    MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™,
    SIMSYS™, and MoleMate™ include hand-held devices that use patented
    technology utilizing light and its remittance to view up to 2 mm beneath
    suspicious moles and lesions in a pain free, non-invasive manner, with
    its software then creating real-time images for physicians and
    dermatologists to evaluate all types of moles or lesions within seconds.
    These products are Health Canada, FDA (US), ARTG and CE cleared for use
    in Canada, the US, Australia, New Zealand, the European Union and
    Turkey. MedX also designs, manufactures and distributes quality
    photobiomodulation therapeutic and dental lasers to provide drug-free
    and non-invasive treatment of tissue damage and pain. www.medxhealth.com.

    This press release does not constitute an offer of any securities for
    sale. This press release contains certain forward-looking statements
    within the meaning of applicable Canadian securities legislation. These
    forward-looking statements involve certain risks and uncertainties that
    could cause actual results to differ, including, without limitation, the
    company’s limited operating history and history of losses, the inability
    to successfully obtain further funding, the inability to raise capital
    on terms acceptable to the company, the inability to compete effectively
    in the marketplace, the inability to complete the proposed acquisition
    and such other risks that could cause the actual results to differ
    materially from those contained in the company’s projections or
    forward-looking statements. All forward looking statements in this press
    release are based on information available to the company as of the date
    hereof, and the company undertakes no obligation to update
    forward-looking statements to reflect events or circumstances occurring
    after the date of this press release.

    Neither TSX Venture Exchange nor its Regulation Services Provider (as
    that term is defined in policies of the TSX Venture Exchange) accepts
    responsibility for the adequacy or accuracy of this press release.

    Contacts

    Scott Spearn, President and CEO
    MedX Health Corp
    905-670-4428
    ext 229

    Media Relations
    Deborah Thompson
    [email protected]
    416-918-9551